Madrigal Pharmaceuticals

Rising Obesity And Aging Trends Will Drive NASH Therapy Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 14 Analysts

Published

26 Aug 25

Updated

26 Aug 25

AnalystHighTarget's Fair Value

US$567.00

25.0% undervalued

26 Aug

US$425.06

70.9%

4.4%

70.9%

4.4%

Author's Valuation

US$567.0

25.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$567.0

25.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

35.88%

Biotech revenue growth rate

12.30%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$1.44b

Earnings '28

11.00x

PE Ratio '28

US$15.88b

Market Cap '28

US$15.88b

Market Cap '28

23.79m

No. shares '28

US$667.36

Share Price '28

US$667.36 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$548.20

Fair Value '25